key: cord-0779220-fdvi9fdw
authors: Andrade, Justin A.; Muzykovsky, Karina; Truong, James
title: Risk factors for mortality in COVID‐19 patients in a community teaching hospital
date: 2021-03-01
journal: J Med Virol
DOI: 10.1002/jmv.26885
sha: a2b77d2d7d212415981df2dbba706bd1a86ac324
doc_id: 779220
cord_uid: fdvi9fdw

As of December 2020, there were over 450,000 confirmed coronavirus disease 2019 (COVID‐19) cases in New York City (NYC) with approximately 25,000 deaths. Previous literature identified advanced age, higher severity of illness, elevated inflammatory biomarkers, acute organ dysfunction, comorbidities, and presentation from long‐term care facility as risk factors for mortality in patients from Wuhan, China, and the United States. Additional studies conducted in NYC are warranted to confirm these findings. The objective of this study was to assess the risk factors for in‐hospital mortality in patients with confirmed COVID‐19 infections. This was a retrospective case‐control study at The Brooklyn Hospital Center, a 464‐bed community teaching hospital. Adult patients with a confirmed COVID‐19 infection and who received at least 24 h of COVID‐19 therapy were included. Univariate and multivariate logistic regression analyses were conducted to identify the risk factors for in‐hospital mortality. Two‐hundred and eighty four patients were included, of whom 95 (33.5%) were nonsurvivors and 189 (66.5%) patients were survivors. Multivariate analysis showed higher in‐hospital mortality with advanced age (odds ratio [OR] 6.476; 95% confidence interval [CI], 1.827–22.953), presentation from long‐term care facility (OR 4.259; 95% CI 1.481–12.250), elevated total bilirubin (OR 4.947; 95% CI 1.048–23.350), vasopressor initiation (OR 36.262; 95% CI 5.319–247.216), and development of renal failure (OR 36.261; 95% CI 2.667–493.046). Risk factors associated with mortality for patients with COVID‐19 in a community teaching hospital included advanced age, vasopressor initiation, development of renal failure, elevated total bilirubin, and presentation from long‐term care facility.

major outbreaks of COVID-19 infections due to its dense population and urbanized environment. As of December 2020, there were over 450,000 confirmed COVID-19 cases in NYC with approximately 70,000 hospitalizations and 25,000 deaths. 3 The crude fatality rate was 9.2% among all confirmed cases and 32.1% among hospitalized patients in NYC within the first three months of the COVID-19 pandemic. Hospital admissions peaked during the week of March 29th and then decreased steadily towards the end of April. 4 Zhou et al. 5 first assessed patients with COVID-19 infections in several hospitals in Wuhan, China and found older age, high Sequential Organ Failure Assessment score, and D-dimer more than 1 μg/ml as independent risk factors for in-hospital mortality. Subsequently, Albitar et al conducted a cross sectional study using worldwide open access data in which they found that male sex, advanced age, comorbidities (e.g., hypertension and diabetes mellitus), and patients located in America were independent risk factors for mortality. 6 Two multicentered studies in NYC and Long Island, NY evaluated the clinical characteristics and outcomes of patients with COVID-19 infections early on during the outbreak in NYC, but neither study assessed risk factors for mortality. 7, 8 In addition, a prospective multicenter observational study conducted in NYC found advanced age, chronic cardiac disease, chronic pulmonary disease, increased interleukin-6, and D-dimer as independent risk factors of in-hospital mortality. 9 Recently, a multicenter retrospective study including over 500 hospitals conducted throughout the United States found that older age was most strongly associated with death.

Likewise, male sex, patients transferred from long-term care facilities, and patients from hospitals from the northeastern portion of the United States were associated with in-hospital mortality in this retrospective study. 10 Although these findings help determine patients at risk for mortality among the United States and NYC population, subsequent studies are needed to confirm these findings.

In this retrospective case-control single-center analysis, we assessed clinical characteristics, outcomes and risk factors for mortality in hospitalized patients with confirmed COVID-19 infections in NYC.

This retrospective study took place at The Brooklyn Hospital Center (TBHC), a 464-bed community teaching hospital. Adult patients, 21 years of age or older, were included if they were admitted to TBHC between March 1, 2020 to April 15, 2020 with moderate to severe COVID-19 infection confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) and received at least 24 h of COVID-19 therapy. The study period was chosen to evaluate patients outcomes at the peak of the pandemic and due to the significant decrease in patients hospitalized for COVID-19 at our institution following this period.

Moderate to severe COVID-19 infection was defined as fulfilling at least one of the following criteria: radiographic evidence of pneumonia as per radiologist's final report, oxygen saturation less than 94% on room air, or requiring supplemental oxygen. Patients were excluded if death occurred before COVID-19 RT-PCR test result or if they were still admitted at the time of data analysis.

This study was approved by The Brooklyn Hospital Center Institutional Review Board (IRBNet ID: 1609888-1). Informed consent was waived for retrospective review of patient charts.

The primary endpoint was risk factors for mortality in patients with 11 Renal failure was defined as acute kidney injury (AKI) Stage 3, which is an increase in serum creatinine greater than or equal to three times from baseline, or an increase greater than or equal to 0.5 mg/dL if the baseline serum creatinine was greater than 4 mg/dL. 12 Development of prolonged QTc was defined as increase of baseline QTc by greater than or equal to 60 ms or increase of baseline QTc greater than 500 ms (if baseline was less than 500 ms). 13 Additional definitions can be found in the Supplementary Material.

Laboratory testing for COVID-19 infection was done using the Ab- 

Data collection and study outcomes were evaluated until May 28, 2020, which is 43 days from the date of the last patient admission.

Baseline demographic data, laboratory measurements, imaging studies, concomitant infection (e.g., bacterial and/or influenza), hospitalization information (e.g., location before admission, hospitalization dates, hospital location, etc.), type of consultation (infectious diseases and/or pulmonary critical care), disease severity at baseline, treatment (e.g., primary antiviral therapy, adjunctive therapy, antibiotic therapy, influenza therapy, new-start therapeutic anticoagulation, e.g., heparin, enoxaparin, direct oral anticoagulant [DOAC], or warfarin), vasopressors, and glucocorticoids) and outcomes were collected from the electronic medical record, All-scripts®, and stored on an encrypted Microsoft Excel® file.

Two-tailed t-tests, Mann-Whitney U, χ 2 , or Fisher's exact tests were performed to compare differences between survivors and nonsurvivors where appropriate; missing data were excluded from data summary and analysis. An α less than .05 was considered statistically significant for all tests. All analyses were conducted using SPSS (version 27.0.; IBM Corp.).

Univariate logistic regression was first used to determine the odds ratios (ORs) and 95% confidence intervals (CIs) for risk factors associated with in-hospital mortality. Nonredundant variables with a p value less than or equal to .20 on univariate logistic regression analysis were included in the multivariate logistic regression analysis.

To avoid overfitting in the multivariate logistic regression model, seventeen independent variables were chosen based on number of deaths in our study. 14 The events per variable was between 5 and 9 thus leading to the inclusion of additional variables compared with previous literature in multivariate logistic regression analysis without exacerbating the risk of relative bias, type I error, and lower confidence interval coverage. 5, 9, 14 2.6.1 | Variables included in multivariate logistic regression analysis Eleven variables were selected based on previous literature that identified these variables as significant risk factors for mortality by multivariate logistic regression: advanced age 5, 6, 9, 10 ; presentation from long-term care facility 10 ; elevated D-dimer 5,9 ; chronic cardiac disease (i.e., coronary artery disease or congestive heart failure) and chronic obstructive pulmonary disease or interstitial disease 9,10 ; elevated total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) 15 ; male sex 6,10,16 ; hypertension 6, 17, 18 ; AKI 10, 19 ; and diabetes. 6, 10 Our study included baseline serum creatinine greater than or equal to 1.5 mg/dL and development of renal failure to assess whether baseline kidney dysfunction is associated with in-hospital mortality. In addition, initiation of renal replacement therapy (RRT) was included as patients in AKI that require RRT have a higher risk of death. 20 ICU admission, invasive mechanical ventilation, and vasopressor initiation were included as literature has shown higher frequency of these variables associated with nonsurvivors compared with survivors. 9 2.6.2 | Variables excluded in multivariate logistic regression analysis Specialist consultation, respiratory rate (RR) greater than or equal to 25 breaths per minute, systolic blood pressure (SBP) less than or equal to 90 mmHg, heart rate (HR) greater than or equal to 125 beats per minute, white blood cell count, lymphocyte count, platelet count, serum ferritin, C-reactive protein, troponin, QTc interval, and bacteremia were not included as prior studies have not shown these categories as independent risk factors for mortality and the investigators avoided risk of overfitting. 5, 9, 14 Similarly, primary antiviral therapy, missed two doses or more of primary antiviral therapy, new start therapeutic anticoagulation, adjunctive therapy, concomitant antibiotic therapy, and glucocorticoid initiation were excluded.

Between March 1st and April 15th, 2020, 284 adults were admitted to The Brooklyn Hospital Center with laboratory-confirmed COVID-19 infections that met inclusion criteria, of which 95 (33.5%) were non-survivors and 189 (66.5%) were survivors.

The majority of demographics and baseline characteristics were different among non-survivors and survivors (Table 1) . It should be noted that nonsurvivors were of older age (p < .001) and were more often males (p = .040), presenting from a nursing home (p < .001), had a specialist consultation (p < .001), and were admitted to the ICU (p < .001). Moreover, nonsurvivors also had a significantly higher rate of coronary artery disease, and diabetes compared with survivors (p < .001, p = .003, respectively). Furthermore, nonsurvivors had significantly worse baseline vital signs, such as, tachypnea (49, 51.6%), tachycardia (24, 25.3%), and hypotension (25, 26 .3%) compared with survivors (p < .001 for all variables). In regard to baseline laboratory and inflammatory parameters, pertinent findings were that nonsurvivors had more lymphopenia (p = .007), D-dimer > 1 μg/ml (p = .048), CRP > 100 mg/L (p = .039), serum ferritin less than 300 μg/L (p = .048); refer to Table 1 for additional significant findings. (Table 3) . D-dimer was not included in the multivariate logistic regression analysis even though it was statistically significant through univariate logistic regression analysis as this parameter had only 59 patients whom had the variable obtained, which would limit the representation of the patient population for a predicator of mortality. ALT was not statistically significant on univariate logistic regression analysis (p = .483) as compared with other pertinent liver injury markers (e.g., total bilirubin and AST) and therefore was excluded from multivariate logistic regression analysis. Our study included 15 As there is limited literature that identified patients transferred from a long-term care facility as an independent risk factor for mortality in patients with COVID-19, 10 a post hoc analysis was conducted to further explore this finding (see Table S1 ). Variables that were included in the exploratory analysis were patient char- literature. 5, 6, 9, 10, 15, 19 Septic shock is commonly seen in patients with COVID-19 infection and seen in up to 70% of nonsurvivors based on data from China 21 and United States. 7, 9, 10 Not surprisingly, patients who were initiated on vasopressors in our study were also found to be at a higher risk for in-hospital mortality.

The findings in our post hoc analysis provides some explanation why patients who were transferred from long-term care facilities were at increased risk for mortality in our study and the study by Rosenthal et al. 10 In our post hoc analysis, we found patients from long-term care facilities had a higher prevalence of coronary artery disease and advanced age (Table S1) , which we previously identified as independent risk factors for in-hospital mortality (Table 3 ). In addition, patients presenting from a long-term care facility had a higher prevalence of hypertension and chronic respiratory disease. and were excluded from analysis. e 33 patients (13 non-survivors and 20 survivors) were excluded as they were on hemodialysis at baseline and/or if serum creatinine was not repeated to assess for renal failure and were excluded from analysis. f 31 patients (12 non-survivors and 19 survivors) were excluded as they were on hemodialysis at baseline and were excluded from analysis.

Although we previously did not find these comorbidities to be independent risk factors for mortality (Table 3) , these were found to be significant mortality risk factors in previous literature. 6, 9, 10 Among the COVID-19 nonsurvivors who were admitted to TBHC during the first month and a half of the city's outbreak, the majority were men over the age of 65 with hypertension and diabetes, one-third were obese, and more than half required supplemental oxygen upon presentation. These findings correspond with previous literature reporting the demographics of patients with COVID-19 in NYC. [7] [8] [9] Interestingly, we did not find hypertension as a risk factor for mortality as compared to previous international reports. 6 Second, as the evaluation of outcomes were halted at a specific date, nine patients in the survivor group were excluded from analysis of 30-readmission. Third, the inclusion period of the study was approximately one and a half months during the COVID-19 pandemic, thus minimizing the potential sample size to evaluate a more accurate assessment of risk factors for mortality in COVID-19 patients.

Fourth, data reported elsewhere have correlated elevated interleukin-6 levels 9 and D-dimer with more severe clinical COVID-19 illness. 5, 9 Unfortunately, interleukin-6 levels are not performed at our institution, limiting our ability to compare to these studies. In addition, D-dimer was not included in multivariate logistic regression analysis as this baseline parameter was not available for the majority of the patient cohort which would limit the representation of risk for in-hospital mortality. Lastly, even though our study evaluated more variables than previous studies, 5, 9 we were unable to assess other potential novel findings due to the risk for overfitting. 14 In conclusion, risk factors associated with mortality for patients with COVID-19 in a NYC community teaching hospital include advanced age, presentation from nursing home or assisted living facility, initiation of vasopressor therapy, development of renal failure, and elevated total bilirubin. We hope our findings and other emerging data will contribute to the development of an international risk stratification tool in hospitalized patients with COVID-19.

We thank the clinical staff at The Brooklyn Hospital Center and worldwide for their exceptional and diligent care of patients. We are grateful to Angella Samson for her assistance with data extraction.

All the authors declare that there are no conflict of interests.

Karina Muzykovsky, James Truong, and Justin A. Andrade had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 

The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.26885.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Justin A. Andrade http://orcid.org/0000-0003-2382-9201

Transmission of SARS-CoV-2: a review of viral, host, and environmental factors

Available at: Novel coronavirus, Wuhan, China Available at: Information for Healthcare Professionals

COVID-19 outbreak -New York city

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors for mortality among COVID-19 patients

Clinical characteristics of COVID-19 in New York City

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Risk factors associated with in-hospital mortality in a us national sample of patients with covid-19

A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19

KDIGO clinical practice guidelines for acute kidney injury

Urgent guidance for navigating and circumventing the QTcprolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)

Relaxing the rule of ten events per variable in logistic and Cox regression

Longitudinal association between markers of liver injury and mortality in COVID-19 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Kidney disease is associated with inhospital death of patients with COVID-19

Renal replacement therapy for acute kidney injury

Clinical characteristics of coronavirus disease 2019 in China

Clinical features and outcomes of 105 hospitalized patients with COVID-19 in

Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Remdesivir and its antiviral activity against COVID-19: a systematic review

Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Compassionate use of remdesivir for patients with severe COVID-19

US Food Drug Administration. 2020. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential

Risk factors for mortality in COVID-19 patients in a community teaching hospital